Ambroxol Lipodisq Sterile Solution

Trans-4-[[(2-amino-3,5-dibromophenyl)methyl]amino]; NA 872; Cyclohexanol

Colourless clear aqueous solution

Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.

23828-92-4

1mg/ml (0.1% w/vol)

32160000

liquid

Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.

Keep sterile. Avoid skin and eye contact.

InChI=1S/C13H18Br2N2O.ClH/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10;/h5-6,10-11,17-18H,1-4,7,16H2;1H/t10-,11-;InChI=1S/C13H18Br2N2O.ClH/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10;/h5-6,10-11,17-18H,1-4,7,16H2;1H/t10-,11-;

QNVKOSLOVOTXKF-PFWPSKEQSA-N

Chemical. CAS: 23828-92-4. Formula: C13H18Br2N2O . HCl. MW: 378.1 . 36.5. Ambroxol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Ambroxol is a mucolytic agent used in the treatment of respiratory diseases. Ambroxol is a basic (pKa = 9.01) cationic drug with lipophilic properties (logP = 2.9), enabling it to act as a lysosomotropic agent. In addition, ambroxol exhibits a novel mechanism by accumulating in lamellar bodies and acting as a lysosomal secretagogue. A wide range of pharmacological effects of ambroxol has been confirmed, including mucus regulation, anti-inflammatory, reduction of arachidonic acid metabolites and pro-inflammatory cytokines, and antioxidant properties. In addition, ambroxol aids in the enhancement of local defense molecules involved in respiratory viral replication. Ambroxol is a sodium channel blocker and mucolytic agent with antioxidant, anti-viral and anti-inflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes. Inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inhibits viral replication and improves the survival rate of mice infected with influenza (H3N2) virus. It is a candidate for use as an anti-COVID19 therapeutic. Ambroxol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.

MFCD00078932

C13H18Br2N2O . HCl

378.1 . 36.5

Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.

Vial

Ambroxol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Ambroxol is a mucolytic agent used in the treatment of respiratory diseases. Ambroxol is a basic (pKa = 9.01) cationic drug with lipophilic properties (logP = 2.9), enabling it to act as a lysosomotropic agent. In addition, ambroxol exhibits a novel mechanism by accumulating in lamellar bodies and acting as a lysosomal secretagogue. A wide range of pharmacological effects of ambroxol has been confirmed, including mucus regulation, anti-inflammatory, reduction of arachidonic acid metabolites and pro-inflammatory cytokines, and antioxidant properties. In addition, ambroxol aids in the enhancement of local defense molecules involved in respiratory viral replication. Ambroxol is a sodium channel blocker and mucolytic agent with antioxidant, anti-viral and anti-inflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes. Inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inhibits viral replication and improves the survival rate of mice infected with influenza (H3N2) virus. It is a candidate for use as an anti-COVID19 therapeutic. Ambroxol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.

>95% (HPLC)

O[C@H]1CC[C@H](NCC2=CC(Br)=CC(Br)=C2N)CC1.Cl

Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).

Non-Hazardous

Biochemical Reagents

12352200

Stable for at least 1 year after receipt when stored at +4°C.